PT  - JOURNAL ARTICLE
AU  - Congly, Stephen E.
AU  - Varughese, Rhea A.
AU  - Brown, Crystal E.
AU  - Clement, Fiona M.
AU  - Saxinger, Lynora
TI  - Treatment of Moderate to Severe Respiratory COVID-19—A Cost-Utility Analysis
AID  - 10.1101/2020.09.21.20199182
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.09.21.20199182
4099  - http://medrxiv.org/content/early/2020/09/22/2020.09.21.20199182.1.short
4100  - http://medrxiv.org/content/early/2020/09/22/2020.09.21.20199182.1.full
AB  - Background Due to COVID-19’s significant morbidity and mortality, identifying the most cost-effective pharmacologic treatment strategy is critical. As such, we determined the most cost-effective strategy for moderate to severe COVID-19 respiratory infections using the United States health care system as a representative model.Methods A decision analytic model modelled a base case scenario of a 60-year-old patient admitted to hospital with COVID-19. Patients requiring oxygen were considered moderate severity, and patients with severe COVID-19 required intubation with intensive care. Strategies modelled included giving remdesivir to all patients, remdesivir in severe infections, remdesivir in moderate infections, dexamethasone to all patients, dexamethasone in severe infections, remdesivir in moderate/dexamethasone in severe infections, and best supportive care. Data for the model came from the published literature. The time horizon was 1 year; no discounting was performed due to the short duration. The perspective was of the payer in the United States health care system.Results Supportive care for moderate/severe COVID-19 cost $11,112.98/0.8256 QALY. Remdesivir in moderate/dexamethasone in severe infections was the most cost-effective with an incremental cost-effectiveness ratio of $19,764.56/QALY gained compared to supportive care. Probabilistic sensitivity analyses showed remdesivir for moderate/dexamethasone for severe COVID-19 infection was most cost-effective in 88.6% of scenarios and dexamethasone in moderate-severe infections in 11.4% of scenarios. With lower willingness to pay thresholds ($250-$37,500), dexamethasone for severe infections was favoured.Conclusions Remdesivir for moderate/dexamethasone for severe COVID-19 infections was the0020most cost-effective strategy. Further data is required for remdesivir to better assess its cost effectiveness in treatment of COVID-19.Competing Interest StatementDr. Congly reports grants from Gilead Sciences, Boehringer Ingelheim, Genfit, Allergan, and Sequana Medical and personal fees from Intercept Pharmaceuticals and Eisai outside the submitted work. Drs. Varughese, Brown, Clement and Saxinger report no potential conflicts of interest.Funding StatementNo external funding was received for this study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics approval was not required as the data used in this study came from publicly available data.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData inputs used for the model are available in Table 1.